Document is current
Any future updates will be listed below
-
Authors
Di Santo, Gianpaolo
Santo, Giulia
Martinovic, Vladan
Wolf, Dominik
Pircher, Andreas
Sviridenko, Anna
Löffler-Ragg, Judith
von Guggenberg, Elisabeth
Virgolini, Irene https://orcid.org/0000-0001-7097-6170
-
Funding
Funding for this research was provided by:
University of Innsbruck and Medical University of Innsbruck
- License Information
-
More Information
Article History
Received: 5 March 2024
Accepted: 28 April 2024
First Online: 14 May 2024
Declarations
:
: All procedures performed in this study were in accordance with the ethical standards of the institutional and/or national research committee. Written informed consent was given by the patient prior to the exams together with the permission for anonymized publication of the related medical data. [<sup>68</sup>Ga]Ga-DOTA-MGS5 was used on a named patient basis and prepared according to the Austrian Medicinal Products Act (AMG §8 and §62).
: The Medical University of Innsbruck has filed a patent application for minigastrin analogues with “Improved pharmacokinetics and cholecystokinin-2 receptor (CCK2R) targeting for diagnosis and therapy”. All other authors have nothing to disclose.
